Area of research
Pathology and Forensic Medicine · Genetics
Research interest
Research interests include Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, CAR-T cell therapy research, and Monoclonal and Polyclonal Antibodies Research.
Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study
Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab
NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025
Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study
Lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pt) with R/R large B-cell lymphoma (LBCL): 3-year follow-up (FU) from the randomized, phase 3 TRANSFORM study.
Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023
Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients with Prior cBTKi: Safety and Efficacy Including High-Risk Subgroup Analyses from the Phase 1/2 BRUIN Study
Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma
Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022
Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021
Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies.
Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study
Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics
Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: <scp>CALGB</scp>/Alliance 50403
NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019
Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era
Radiological imaging and bone marrow biopsy in staging of cutaneous B-cell lymphoma.
NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018
Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology
Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017
<scp>C‐MYC</scp>–positive relapsed and refractory, diffuse large <scp>B</scp>‐cell lymphoma: Impact of additional “hits” and outcomes with subsequent therapy